De Renon Biotec Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.96 Cr
- Revenue Growth 9.51%
- Profit Growth -12.96%
- Ebitda -5.52%
- Net Worth 33.77%
- Total Assets 48.66%
About De Renon Biotec
De Renon Biotec Private Limited (DRBPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 November 2016 (Eight years and three months 26 days old ). Its registered office is in Thiruvananthapuram, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.96 Cr.
Janardhanan Nair and Salini Harish serve as directors at the Company.
Company Details
- Location
Thiruvananthapuram, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U51397KL2016PTC047177
- Company No.
047177
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Nov 2016
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Pharma
Who are the key members and board of directors at De Renon Biotec?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Salini Harish  | Director | 02-Nov-2016 | Current |
| Janardhanan Nair | Director | 02-Nov-2016 | Current |
Financial Performance of De Renon Biotec.
De Renon Biotec Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 9.51% increase. The company also saw a substantial fall in profitability, with a 12.96% decrease in profit. The company's net worth Soared by an impressive increase of 33.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of De Renon Biotec?
In 2020, De Renon Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹19.55 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Others : 1.00 Cr
- Hdfc Bank Limited : 0.96 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Aug 2024 | Hdfc Bank Limited | ₹1.00 M | Open |
| 30 Oct 2023 | Hdfc Bank Limited | ₹3.60 M | Open |
| 30 Nov 2022 | Others | ₹1.00 Cr | Open |
| 25 Jul 2022 | Hdfc Bank Limited | ₹4.95 M | Open |
How Many Employees Work at De Renon Biotec?
Unlock and access historical data on people associated with De Renon Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of De Renon Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped De Renon Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.